LAVA Therapeutics N.V. (LVTX)
AI Score
Our AI model analyzes fundamental, technical, and statistical indicators
to predict the probability of a bullish trend over the next three months.
We regularly update and refine our models to deliver the most reliable forecasts
for you.
Bullish Probability | Sentiment | Score |
---|---|---|
+80% | Strong Buy | 10 |
+75% | Buy | 9 |
+70% | Buy | 8 |
+60% | Buy | 7 |
+50% | Hold | 6 |
+45% | Hold | 5 |
+40% | Hold | 4 |
+35% | Sell | 3 |
+30% | Sell | 2 |
+20% | Strong Sell | 1 |
Bid | 0.96 |
Market Cap | 25.24M |
Revenue (ttm) | - |
Net Income (ttm) | - |
EPS (ttm) | -1.01 |
PE Ratio (ttm) | -0.95 |
Forward PE | n/a |
Analyst | Hold |
Ask | 1 |
Volume | 9,109 |
Avg. Volume (20D) | 105,615 |
Open | 0.97 |
Previous Close | 0.94 |
Day's Range | 0.96 - 0.98 |
52-Week Range | 0.88 - 6.47 |
Beta | undefined |
About LVTX
LAVA Therapeutics N.V., a clinical-stage immuno-oncology company, focuses on developing cancer treatments. The company, through its Gammabody platform, develops a portfolio of novel bispecific antibodies to engage and leverage the potency and precision of gamma delta T cells to elicit an anti-tumor immune response and enhance outcomes for cancer patients. Its lead clinical-stage candidates are LAVA-051, which is in Phase 1/2a clinical trial for b...
Analyst Forecast
According to 3 analyst ratings, the average rating for LVTX stock is "Hold." The 12-month stock price forecast is $2, which is an increase of 108.31% from the latest price.
Next Earnings Release
Analysts project revenue of ... Unlock content with Pro Subscription
Why Price Moved
News

6 months ago · 247wallst.com
4 Stocks Under $5 To Buy NowAre you looking for stocks to buy with low price tags?